Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health is projected to experience a compound annual growth rate of adjusted EBITDA between 5% and 8% through 2027, indicating potential margin expansion of 50 to 150 basis points. The company is also expected to achieve an additional 90 basis points of adjusted EBITDA margin improvement from its Sterigenics business from 2025 to 2028, while maintaining stable margins for its Nordion and Nelson Labs segments. With a strategic shift towards higher-margin lab testing services and a successful initial execution of its cross-selling strategy, Sotera is well-positioned for adjusted gross profit growth at a compound annual rate of 6.4%, reflecting ongoing operational efficiencies and increased market penetration.

Bears say

Sotera Health has experienced a decline in adjusted EBITDA margins, dropping 180 basis points from 51.7% in 2021 to 49.9% in 2024, primarily due to inflation, overstaffing, and a negative mix within its Nelson Labs segment. The company's earnings outlook is further compounded by a significant reduction in sales from higher-margin COVID-related testing and poor performance in advisory services, which is projected to adversely affect Nelson Labs sales by 10 points in 2025. Additionally, despite prior organic revenue growth of 9.0% from 2021 to 2022, ongoing customer supply chain issues and a strategic shift toward lower-margin services have led to increased financial pressure on the firm.

Sotera Health (SHC) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 6 analysts, Sotera Health (SHC) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.